Corcept Therapeutics (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to treat a type of ovarian cancer met its primary goal, sending shares up more than 90% in recent premarket trading activity.
The company said the study showed a 30% reduction in the risk of disease progression for patients treated with relacorilant and nab-paclitaxel compared to those receiving nab-paclitaxel alone.
The drug developer said the median progression-free survival assessed by blinded independent central review was 6.5 months for the combination therapy group, compared to 5.5 months for those on nab-paclitaxel alone.
In an interim evaluation of overall survival, the company said the combination therapy group showed a significant improvement, with a median overall survival of 16 months versus 11.5 months for the control group.
It added the combination therapy was well-tolerated, with no increased side effect burden.
Corcept said it plans to submit a new drug application for the therapy in Q3.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.